Yes, vancomycin is classified as a vesicant. The Infusion Nurses Society (INS), which sets the standard for intravenous therapy practice, explicitly identifies vancomycin as a vesicant in its 2021 Standards of Practice. This means that if the drug leaks out of a vein and into surrounding tissue during infusion, it can cause blistering, tissue damage, and in severe cases, skin necrosis.
Vesicant vs. Irritant: Where Vancomycin Falls
Drugs given intravenously are generally sorted into three categories based on the harm they cause if they escape the vein. Nonvesicants cause little to no damage. Irritants cause pain, inflammation, and local swelling but typically don’t destroy tissue. Vesicants are the most dangerous category: they can cause blistering, ulceration, and tissue death that sometimes requires surgical intervention.
You’ll sometimes see vancomycin described as an “irritant” in older references or informal clinical discussions, partly because its tissue damage profile looks different from the most notorious vesicants used in chemotherapy. However, published case reports document full-thickness skin necrosis from vancomycin extravasation, and the INS now clearly labels it a vesicant. The 2021 INS standards specifically warn that “vancomycin, a vesicant, is sometimes intermittently infused via a midline catheter at home” and that careful evaluation of appropriateness and duration is essential.
Why Vancomycin Damages Tissue
The main reason vancomycin is harmful to tissue is its acidity. Standard vancomycin solutions have a pH between 3.0 and 5.0, making them quite acidic compared to your body’s normal pH of around 7.4. That low pH irritates the walls of veins during normal infusion and can directly destroy cells if the fluid leaks into the surrounding soft tissue.
When extravasation occurs, the acidic solution essentially burns the tissue from the inside. A case report in the British Journal of Clinical Pharmacology described this mechanism: the drug’s low pH has a direct irritant effect on the vascular wall, and once the solution escapes into tissue (whether through a dislodged catheter or through capillary leakage), it causes necrosis. The damage can range from mild redness and swelling to deep tissue destruction requiring wound care over weeks.
How Concentration and Infusion Rate Matter
The risk of tissue injury increases with higher drug concentrations. Clinical guidelines recommend that vancomycin given through a peripheral IV should not exceed 5 mg/mL, meaning a standard 1-gram dose needs to be diluted in at least 200 mL of fluid. Through a central line, the maximum concentration doubles to 10 mg/mL because the drug enters a larger, faster-flowing blood vessel where it’s diluted almost immediately.
Infusion rate matters too. Vancomycin is typically given slowly, often over 60 minutes or more, partly to reduce the risk of “red man syndrome” (a histamine-related flushing reaction) and partly to protect the vein. Faster infusion concentrates the acidic solution along the vein wall, raising the chance of phlebitis (vein inflammation) and making extravasation more likely to cause serious damage if it occurs.
What Happens if Vancomycin Extravasates
If you’re receiving vancomycin through an IV and notice sudden burning, stinging, swelling, or redness at the infusion site, the line may have shifted and the drug could be leaking into tissue. The infusion should be stopped immediately. Early recognition is the single most important factor in limiting damage.
For vancomycin specifically, warm compresses are the recommended first-line response. The goal is to dilute and disperse the drug across a wider area of tissue so it doesn’t concentrate in one spot. Cold compresses are not recommended because they cause blood vessels to constrict, which traps the acidic drug in a small area and can worsen the injury. An enzyme called hyaluronidase may also be injected into the area to help break down tissue barriers and allow the drug to spread and be reabsorbed more quickly.
Mild cases resolve with redness and tenderness that fades over days. Severe cases, particularly when a large volume of concentrated vancomycin escapes the vein, can produce blistering and tissue death that takes weeks to heal and may need surgical cleaning of the wound.
Choosing the Right IV Access
Because vancomycin is a vesicant, the type of IV access used for treatment is a meaningful clinical decision, especially for longer courses. Short peripheral IVs work for brief treatments of a few days, provided the site is monitored closely and the concentration stays at or below 5 mg/mL. The INS standards recommend increased surveillance frequency when a vesicant is infused intermittently for more than six days through any peripheral device, because the risk of phlebitis and extravasation climbs with repeated exposure.
For longer courses, such as the four-to-six-week regimens used for bone or heart valve infections, a centrally placed catheter (like a PICC line) is often preferred. Central lines deliver the drug into large central veins where blood flow is high and dilution is rapid, substantially reducing the risk of local tissue injury. Midline catheters, which sit in the upper arm but don’t reach central veins, are sometimes used for outpatient vancomycin therapy as a middle-ground option, though the INS specifically flags this practice as one requiring careful evaluation.